Recent Quotes
My Watchlist
Indicators
Local Stocks
Deseret News Composite
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beta Bionics, Inc. - Common Stock (NQ:BBNX)

28.82 +4.54 (+18.70%)
Streaming Delayed Price Updated: 9:33 AM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Beta Bionics, Inc. - Common Stock

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Wondering what's happening in today's after-hours session?
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
Beta Bionics Inc (NASDAQ:BBNX) Tops Q3 2025 Revenue Estimates and Raises Full-Year Guidance
Beta Bionics (BBNX) beat Q3 2025 revenue estimates and raised its full-year guidance. The medical device company reported strong user growth and a narrower-than-expected loss. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Earnings Scheduled For October 28, 2025
 
Via Benzinga
Beyond The Numbers: 6 Analysts Discuss Beta Bionics Stock
 
Via Benzinga
Earnings Scheduled For July 29, 2025
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
Demystifying Beta Bionics: Insights From 5 Analyst Reviews
 
Via Benzinga
Forecasting The Future: 4 Analyst Projections For Beta Bionics
 
Via Benzinga
Beta Bionics (BBNX) Q2 Revenue Soars 54%
Via The Motley Fool
Topics Intellectual Property
Beta Bionics BBNX Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Beta Bionics Inc (NASDAQ:BBNX) Surpasses Q2 2025 Estimates and Raises Full-Year Guidance
Beta Bionics (BBNX) beats Q2 2025 revenue and EPS estimates, raises full-year guidance. Shares surge 5.7% as iLet Bionic Pancreas and new insulin pump drive growth. 
Via Chartmill
Sonnet BioTherapeutics Drops 5% Intraday, Rebounds 14% After Hours Amid Delisting Concerns
Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) fell 5.54% on Thursday to close at $3.92, before rebounding 14.29% in after-hours trading to $4.48, amid concerns of a potential NASDAQ delisting. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges
Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral. 
Via Benzinga
Beta Bionics Stock Gains After Mixed Analyst Coverage; Wolfe Bullish, Goldman Neutral
Wolfe Research initiated coverage with an ‘Outperform’ rating and a $20 target, while Goldman Sachs started at ‘Neutral’ with a $16 target, citing balanced growth prospects and valuation. 
Via Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Earnings Scheduled For March 25, 2025
 
Via Benzinga
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Infinity Natural Resources Valued At $1.3 Billion In Market Debut
Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3 billion. The listing arrived amid a more fossil fuel-friendly White House... 
Via Talk Markets
Topics Energy Stocks / Equities
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.